Press Release

Morgan Lewis Advises MediSix Therapeutics in $20 Million Series A Funding

May 23, 2018

SINGAPORE, May 23, 2018: Morgan Lewis represented MediSix Therapeutics, a development-stage cell therapy company targeting T-cell leukemia and lymphoma, in a $20 million Series A funding.

The financing, announced on May 15, was led by Lightstone Ventures with participation from Temasek and Osage University Partners. 

The Morgan Lewis team representing MediSix was led by partners Jeffry Mann, Scott Karchmer and Edward Bennett, with support from associates Corey Mueller and Jeremiah Huang.